MedOne, L.C. – Trademark Portfolio
Entity Type: 16
MedOne, L.C. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 4 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include RXALLY, MYMEDONE, and ONWARDRX. The owner is based in Dubuque, IA.
1590 University Avenue
Dubuque, IA 52001
Showing of trademarks Trademarks
Trademark Classifications
MedOne, L.C.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does MedOne, L.C. have?
MedOne, L.C. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does MedOne, L.C. file in?
MedOne, L.C. files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 35 covers advertising; business management; business administration; office functions.
What are MedOne, L.C.'s most well-known trademarks?
MedOne, L.C.'s registered trademark portfolio includes well-known marks such as RXALLY, MYMEDONE, and ONWARDRX. These are among 3 currently registered trademarks in the portfolio.
What is MedOne, L.C.'s trademark registration success rate?
MedOne, L.C. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.